Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
Ali ManouchehriniaHanna LarssonMohammad Ehsanul KarimJan N LyckeTomas OlssonIngrid KockumPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Treatment with natalizumab or other monoclonal antibodies is associated with a significantly faster likelihood of cognitive improvement than platform or oral DMTs.